The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
Open accessAbstract
BACKGROUND: Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density. METHODS: We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 microg subcutaneously daily; 27 men), or both (28 men). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured at base line and month 30 by means of quantitative computed tomography. Serum alkaline phosphatase levels were measured every six months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine. RESULTS: The bone mineral density at the lumbar spine increased significantly more in men treated with parathyroid hormone alone than in those in the other groups (P<0.001 for both comparisons). The bone mineral density at the femoral neck increased significantly more in the parathyroid hormone group than in the alendronate group (P<0.001) or the combination-therapy group (P=0.01). The bone mineral density of the lumbar spine increased significantly more in the combination-therapy group than in the alendronate group (P<0.001). At 12 months, changes in the serum alkaline phosphatase level were significantly greater in the parathyroid hormone group than in the alendronate group or the combination-therapy group (P<0.001 for both comparisons). CONCLUSIONS: Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men. This effect may be attributable to an attenuation of parathyroid hormone-induced stimulation of bone formation by alendronate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationBlack, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
(1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-486_3 · Cited by 2,056
(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Orwoll, E., Scheele, W., Paul, S., Adami, S., Syversen, U., Diez-Perez, A., Kaufman, J.-M., Clancy, A., & Gaich, G. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.1.9 · Cited by 776
Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., & Cosman, F. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02342-8 · Cited by 749
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Interventions for enhancing medication adherence
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub3 · Cited by 1,244
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Khosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Mechanisms of Anabolic Therapies for Osteoporosis
Canalis, E., Giustina, A., & Bilezikian, J. P. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067395 · Cited by 668
Osteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 659
Engelke, K., Adams, J. E., Armbrecht, G., Augat, P., Bogado, C. E., Bouxsein, M. L., Felsenberg, D., Ito, M., Prevrhal, S., Hans, D. B., et al. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.010 · Cited by 617
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
Self-citationOne Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Hodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Harris, D. W., Conrad Johnston, C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 605
Arterial Calcifications and Bone Histomorphometry in End-Stage Renal Disease
London, G. M., Marty, C., Marchais, S. J., Guerin, A. P., Metivier, F., & de Vernejoul, M.-C. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000129337.50739.48 · Cited by 594
miR-214 targets ATF4 to inhibit bone formation
Wang, X., Guo, B., Li, Q., Peng, J., Yang, Z., Wang, A., Li, D., Hou, Z., Lv, K., Kan, G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3026 · Cited by 559
An, J., Yang, H., Zhang, Q., Liu, C., Zhao, J., Zhang, L., & Chen, B. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.01.024 · Cited by 526
Interventions for enhancing medication adherence
Haynes, R., Yao, X., Degani, A., Kripalani, S., Garg, A., & McDonald, H. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub2 · Cited by 517
Tsai, J. N., Uihlein, A. V., Lee, H., Kumbhani, R., Siwila-Sackman, E., McKay, E. A., Burnett-Bowie, S.-A. M., Neer, R. M., & Leder, B. Z. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60856-9 · Cited by 496
Self-citationDifferential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
Ettinger, B., Martin, S. J., Crans, G., & Pavo, I. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040117 · Cited by 487
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 478
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1762 · Cited by 444
Periosteum: biology, regulation, and response to osteoporosis therapies
Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 431
Osteoclasts: more than ‘bone eaters’
Charles, J. F., & Aliprantis, A. O. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.001 · Cited by 391
Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers
McComsey, G. A., Tebas, P., Shane, E., Yin, M. T., Overton, E. T., Huang, J. S., Aldrovandi, G. M., Cardoso, S. W., Santana, J. L., & Brown, T. T. (2010) · Clinical Infectious Diseases · doi:10.1086/656412 · Cited by 396
Glucocorticoids suppress bone formation via the osteoclast.
Kim, H.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28084 · Cited by 384
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Cosman, F., Eriksen, E. F., Recknor, C., Miller, P. D., Guañabens, N., Kasperk, C., Papanastasiou, P., Readie, A., Rao, H., Gasser, J. A., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.238 · Cited by 359
Building bone to reverse osteoporosis and repair fractures
Khosla, S., Westendorf, J. J., & Oursler, M. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33612 · Cited by 353
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Kaufman, J.-M., Orwoll, E., Goemaere, S., San Martin, J., Hossain, A., Dalsky, G. P., Lindsay, R., & Mitlak, B. H. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1713-3 · Cited by 320
Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080506 · Cited by 290
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Burnett-Bowie, S.-A. M., Zhu, Y., Foley, K., Lee, H., & Neer, R. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4440 · Cited by 282
Self-citationRegulation of TNF-Induced Osteoclast Differentiation
Yao, Z., Getting, S. J., & Locke, I. C. (2021) · Cells · doi:10.3390/cells11010132 · Cited by 280
“It has also shown that combined therapy with teriparatide and a bisphosphonate does not appear to offer advantages over the use of the single agent alone [31,32].”
BackgroundLindsay, R., Cosman, F., Zhou, H., Bostrom, M. P., Shen, V. W., Cruz, J. D., Nieves, J. W., & Dempster, D. W. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051109 · Cited by 277
Bolotin, H. H. (2007) · Bone · doi:10.1016/j.bone.2007.02.022 · Cited by 274
“A number of the most salient of these have been highlighted in recent research studies, mini-reviews, and perspective journal articles [1–21].”
BackgroundPapapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3234-7 · Cited by 274
Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis
Finkelstein, J. S., Wyland, J. J., Lee, H., & Neer, R. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1703 · Cited by 265
Self-citationParathyroid hormone: a double-edged sword for bone metabolism
Qin, L., Raggatt, L. J., & Partridge, N. C. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.01.006 · Cited by 263
Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia
London, G. M., Marchais, S. J., Guérin, A. P., & Métivier, F. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000168336.67499.c0 · Cited by 258
Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043801 · Cited by 256
Boonen, S., Marin, F., Obermayer-Pietsch, B., Simões, M. E., Barker, C., Glass, E. V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0711 · Cited by 252
Weivoda, M. M., Chew, C. K., Monroe, D. G., Farr, J. N., Atkinson, E. J., Geske, J. R., Eckhardt, B., Thicke, B., Ruan, M., Tweed, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14003-6 · Cited by 230
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Re-thinking the bone remodeling cycle mechanism and the origin of bone loss
Delaisse, J.-M., Andersen, T. L., Kristensen, H. B., Jensen, P. R., Andreasen, C. M., & Søe, K. (2020) · Bone · doi:10.1016/j.bone.2020.115628 · Cited by 152
Burnett-Bowie, S.-A. M., McKay, E. A., Lee, H., & Leder, B. Z. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0739 · Cited by 146
Self-citationOsteoclasts secrete non-bone derived signals that induce bone formation
Karsdal, M. A., Neutzsky-Wulff, A. V., Dziegiel, M. H., Christiansen, C., & Henriksen, K. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.168 · Cited by 112
Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80
Buxton, E. C., Yao, W., & Lane, N. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032066 · Cited by 79
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Bakr, M. M., Kelly, W. L., Brunt, A. R., Paterson, B. C., Massa, H. M., Morrison, N. A., & Forwood, M. R. (2020) · JBMR Plus · doi:10.1002/jbm4.10387 · Cited by 4
Metadata
- Authors
- Finkelstein, J. S., Hayes, A., Hunzelman, J. L., Wyland, J. J., Lee, H., & Neer, R. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-25
- Volume
- 349
- Issue
- 13
- Pages
- 1216-1226
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2013599591
- Cited by
- 829
- References
- 38
- FWCI
- 72.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.